View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
March 10, 2021

Covid-19 cases in the UK down 92% since January

On 7 March, the UK reported 5,265 confirmed Covid-19 cases, its lowest number since the second wave peak of more than 68,000 cases on 8 January. This significant decline means the country has seen a 92% decrease in daily confirmed cases in just under two months, emphasising the effectiveness of the implemented public health measures, specifically the national lockdown, social distancing measures and vaccinations.

By clinicaltrial arena

On 7 March, the UK reported 5,265 confirmed Covid-19 cases, its lowest number since the second wave peak of more than 68,000 cases on 8 January. This significant decline means the country has seen a 92% decrease in daily confirmed cases in just under two months, emphasising the effectiveness of the implemented public health measures, specifically the national lockdown, social distancing measures and vaccinations.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Since Covid-19 vaccinations in the UK began on 8 December, more than 21.9 million first doses have been administered, covering more than 32% of the UK population. The reproduction number (R number) denotes the average number of secondary infections produced by a single infected person and is used to monitor how rapidly an infection is spreading in a given population. The R number range for the UK has fallen to 0.7–0.9 from 1.0–1.4 in January, indicating that the number of transmissions has been significantly reduced because of the public health interventions.

GlobalData epidemiologists produced a two-week prediction forecast on confirmed Covid-19 cases in countries with available historic data. As shown by the graph below, the number of confirmed cases is predicted to decrease in the next two weeks, with the possibility of falling as low as around 1,053 cases by 21 March. This is in line with historical patterns of recovery that had been achieved with public health measures.

On 28 February, Public Health England announced that six new cases of the Brazilian Covid-19 variant had been identified, all linked to travellers arriving from Brazil. Given the awareness of new variants, further measures have been introduced, including restricting travel from high-risk countries. Researchers are still learning about new variants and caution is being taken to ensure that their spread is limited, especially as the efficacy of the current vaccines against these variants is not yet known.

The UK national lockdown is being eased, with schools now reopened and plans in place for non-essential industries to open in April. This increased level of social interaction will be a true test of the effectiveness of vaccinations in limiting the spread of the virus. If the R number continues to fall, the end of the pandemic may be in sight.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena